Related Experiment Video

Updated: May 14, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients

N Nuber, A Curioni-Fontecedro, S R Dannenmann

    Leukemia
    |February 23, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Murine Model of CD40-activation of B cells
    12:24

    Murine Model of CD40-activation of B cells

    Published on: March 5, 2010

    Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
    12:08

    Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

    Published on: May 17, 2019

    Related Experiment Videos

    Last Updated: May 14, 2026

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    Murine Model of CD40-activation of B cells
    12:24

    Murine Model of CD40-activation of B cells

    Published on: March 5, 2010

    Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
    12:08

    Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

    Published on: May 17, 2019

    Related Concept Videos

    Cytotoxic T Cells-mediated Immune Response01:27

    Cytotoxic T Cells-mediated Immune Response

    Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
    Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

    Articles linked to this work by shared authors, journal, and citation graph.

    Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

    ESMO open·2025

    [Vomitus in a white shepherd dog - What's your diagnosis?]

    Schweizer Archiv fur Tierheilkunde·2025

    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

    Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

    ESMO open·2023

    Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches.

    Pathology, research and practice·2023

    Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

    ESMO open·2022

    Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

    Leukemia·2026

    Cheminformatic identification of small molecules targeting acute myeloid leukemia.

    Leukemia·2026

    Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

    Leukemia·2026

    Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

    Leukemia·2026

    PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.

    Leukemia·2026

    TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

    Leukemia·2026

    Hyper-Intense Tumor Peripheral Accumulation of Antibody-Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Concurrent Kaposi Sarcoma and B-cell Lymphoma in an HIV-Negative Patient: A Case Report.

    Cureus·2026

    A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy.

    ACS central science·2026

    Nanotechnology-enabled immunomodulation in esophageal cancer: targeting the tumor microenvironment to overcome therapeutic barriers.

    Frontiers in immunology·2026

    Interpretation of p53 immunohistochemical stain of TP53-mutated myeloid neoplasms.

    Frontiers in oncology·2026

    miR-155-5p drives coordinated tumor and macrophage reprogramming across multiple cancer entities.

    BMC medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us